Written Protocol · PharmD
New Jersey Written Protocol for Pharmacists
Required. The Written Protocol is the written instrument New Jersey law names for a Pharmacist working with a physician. Below: the board that governs it, what it must contain, and the terms it has to carry.
Represents NJ's pharmacist drug-therapy-management Collaborative Practice Agreement (CPA) tier (N.J.S.A. 45:14-61; N.J.A.C. 13:35-6.27), not ordinary dispensing licensure, which needs no physician agreement and is out of scope here. Naloxone prescribing (2023 law) and self-administered hormonal contraceptives (N.J.S.A. 45:14-67.9, via a statewide Board of Pharmacy/BME-approved protocol) are separate authorities that do NOT require an individual CPA with a specific physician — see agreementRequiredNote.
What a New Jersey Written Protocol must contain
Governed by the New Jersey Board of Pharmacy. Each numbered item is a statutory requirement the agreement must satisfy.
The Pharmacist ("Pharmacist") may engage in collaborative drug therapy management of a specific patient under a written protocol with the Physician, initiated at the Physician's sole discretion and with the patient's consent, as required by N.J.S.A. 45:14-61 and N.J.A.C. 13:39-13. The protocol shall identify, by name and title, each physician and pharmacist permitted to participate in the patient's collaborative drug therapy management, specify the Pharmacist's functions and responsibilities, and be kept available at the practice sites of both the Pharmacist and the Physician.
Source: N.J.S.A. 45:14-61; N.J.A.C. 13:39-13
The protocol shall establish when the Pharmacist must notify the Physician of any change in the dose, duration, or frequency of a prescribed medication, and the interval for the Physician's chart review. The protocol may remain in effect for no more than two (2) years, at which point the parties shall review it, either party may terminate it in writing, and the patient must be advised of the right to participate in or withdraw from the arrangement.
- The Written Protocol on file also carries 1 scope, 1 education, 1 registration, 1 authority clauses, generated in the document itself.
Terms it has to carry
Ratio, proximity, chart review, meeting and prescribing terms the agreement has to carry, from the state's supervision rules.
Proximity
Not codified — left to the agreement
Supervision ratio
Not codified — no cap on file
Chart review
Percentage set by agreement · Annually
No fixed chart-review percentage is codified — the collaborating physician must 'establish a method for monitoring both compliance with the collaborative practice agreement and clinical outcomes,' with the protocol itself reviewed at least annually (N.J.A.C. 13:35-6.27). Percentage is therefore omitted rather than set to 0.
Meeting cadence
Annually
Each protocol must be reviewed at least once per year by the physician and pharmacist to determine whether it should be renewed, modified, or terminated (N.J.A.C. 13:35-6.27); no in-person format is specified.
Prescriptive authority
Covered by the practice agreement · no controlled-substance authority
Physician notification timing, chart-update interval, and a protocol-change notice window must all be specified in the protocol itself — no statewide default is fixed.
Written agreement
Required
True for the drug-therapy-management CPA tier this entry represents. But naloxone dispensing and hormonal-contraceptive furnishing are authorized under separate, statewide standardized protocols rather than a per-pharmacist agreement with a named physician — a pharmacist can exercise those two authorities without entering any individual CPA at all.
Practice ownership (corporate practice of medicine)
Non-licensee ownership permitted — This research pass did not locate a confirmed NJ statute restricting retail-pharmacy ownership to licensed pharmacists — treated here as consistent with the common multi-state pattern (non-pharmacist/corporate ownership allowed, with a designated pharmacist-in-charge retaining professional control over dispensing), but this specific citation is unverified for New Jersey and should be confirmed before relying on it.
Materially more permissive than the medical-PC CPOM regime governing PA/NP/CRNA/CNM/CNS above, consistent with how other states in this dataset treat pharmacy ownership — but flagged as unconfirmed rather than sourced, unlike those other entries.
Legal sources for these rules (5)
- N.J.S.A. 45:14-61 — Pharmacy Practice Act, collaborative practice agreements
- N.J.A.C. 13:35-6.27 — Standards for collaborative practice for drug therapy management with licensed pharmacistssecondary
- N.J.S.A. 45:14-67.9 — Pharmacist furnishing of self-administered hormonal contraceptives
- N.J.A.C. 13:39-14.1 — Protocol for pharmacists furnishing self-administered hormonal contraceptivessecondary
- P.L. 2023, c.2 (S275) — pharmacist naloxone prescribing authority
About New Jersey's rules
S2996/A4052 (signed 3/30/2026) grants APNs in primary/behavioral-health population foci independent practice at ≥5,000 hours, ending the COVID-era waiver — but implementing regulations were not yet adopted at this writing, so several details below rely on bill text/press coverage, not a finalized rule. NJ's Professional Service Corporation Act (N.J.S.A. 14A:17-1 et seq.) is notably strict CPOM: only physicians may hold equity in a medical PC.
Other clinicians in New Jersey: see the state overview.